Background: Malignant melanoma, a tumor arising from melanocytes, remains a significant global health challenge due to its high metastatic potential and increasing incidence, particularly in Western populations. While it represents a small fraction of skin cancers, it accounts for the majority of skin cancer-related deaths. Objective: This article provides a comprehensive overview of the current landscape of melanoma, covering its epidemiology, clinical and histological diagnosis, staging, and evolving therapeutic strategies. Methods: A review of clinical characteristics (ABCDE criteria), histopathological markers (Breslow thickness, Clark level), and molecular profiles (BRAF, NRAS, KIT mutations) was conducted based on the latest international guidelines, including AJCC 8th edition and ESMO 2025. Results: Early diagnosis is critical, as 5-year survival rates exceed 95% for localized lesions (Breslow < 0.75 mm) but drop significantly for regional and distant metastatic disease. The diagnostic process has been enhanced by dermoscopy and specific immunohistochemical markers such as PRAME and HMB-45. Furthermore, the management of advanced stages has been revolutionized by the introduction of neoadjuvant and adjuvant immunotherapies (anti-PD-1) and targeted therapies (BRAF/MEK inhibitors), which have significantly improved progression-free and overall survival. Conclusion: The prognosis of melanoma is increasingly dependent on molecular characterization and the timely integration of systemic therapies. While surgical excision remains the gold standard for early-stage disease, the shift toward multidisciplinary neoadjuvant approaches marks a new era in the treatment of high-risk patients.
